Footnotes:
. . .continued from the previous page.

1. Lehninger AL (1970) : Biochemistry, Worth Publisher Inc. 1970
2. Klingenberg M. (1960) : Zur Bedeutung der freien Nucleotide. 11.Mobster Kolloquium Springer Verlag p82-114.
3. Sauberlich HE (1987) : Nutritional Aspects of Pyridine Nucleotides, in Dolphin D, Poulson r, Avramovic O (editors) : Pyridine Nucleotide Coenzymes (Part B), John Wiley & Sons, Inc. 1987, pp. 599-626.
4. Alberts B, et al (1983) : Molecular Biology of the Cell, Garland Publishing, 1983, pp. 491-495
5. Vrecko K, Birkmayer JGD and Krainz J (1993) : Stimulation of dopamine biosynthesis in cultured PC12 phaeochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH), J. Neur Trans. 5:147-156.
6. Gardier M. (1994) Study Report to Labor Birkmayer, Department Pharmacology, University Paris Sud.
7. Kaplan NO (1960) in Boyer PD, Lardy H and Myrbaeck K: The Enzymes Vol. 3, Ac Press New York p.156-172.
8. Birkmayer JGD, Birkmayer W (1989): Stimulation of endogenous L-dopa biosynthesis- a new principle for the therapy of Parkinson’s disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamid adenine dinucleotidephosphate (NADPH), Acta Neurol.Scand.126:183-187.
9. Birkmayer W, Birkmayer JGD (1989): Nicotinamid-adenine-dinucleotide (NADH): The new approach in the therapy of Parkinson’s disease, Ann Clin Sci 19:38-43.
10. Birkmayer W, Birkmayer JGD, Vrecko K and Paletta B (1990): The Clinical Benefit of NADH as Stimulator of Endogenous L-Dopa Biosynthesis in Parkinsonian Patients, Advances in Neurology Vol. 53: Parkinson’s Disease anatomy, Pathology and Therapy 545-549.
11. Birkmayer W, Birkmayer JGD, Vrecko K, Paletta B, Reschenhofer E and Ott E (1990): Nicotinamide Adenine Dinucleotide (NADH) as medication for Parkinson’s disease: Experience with 415 patients, New Trends in Clin. Neuropharm. 4:7-24.
12. Birkmayer W, Birkmayer JGD (1991): Nicotinamide Adenine Dinucleotide (NADH) as medication for depressed patients: Experience with 205 patients, New Trends in Clin. Neuropharm. 5:15-23.
13. Birkmayer JGD, Vrecko K, Volc D and Birkmayer W. (1993) : Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson’s disease: Comparison of oral and parenteral application, Acta Neurol.Scand 87: Suppl.146:32-35.
14. Birkmayer JGD (1995): Nicotinamide adenine dinucleotide (NADH) The new therapeutic approach for improving dementia of the Alzheimer type, submitted for publication.

. . . continue to the next page